229 related articles for article (PubMed ID: 37605223)
21. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Gu J; Huang W; Wang X; Zhang J; Tao T; Zheng Y; Liu S; Yang J; Chen ZS; Cai CY; Li J; Wang H; Fan Y
Mol Cancer; 2022 May; 21(1):112. PubMed ID: 35538494
[TBL] [Abstract][Full Text] [Related]
22. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
23. N6-methyladenosine demethylase FTO related to hyperandrogenism in PCOS via AKT pathway.
Jing YX; Li HX; Yue F; Li YM; Yu X; He JJ; Zhang XH
Gynecol Endocrinol; 2023 Oct; 39(1):2276167. PubMed ID: 37931646
[TBL] [Abstract][Full Text] [Related]
24. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
[TBL] [Abstract][Full Text] [Related]
25. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma.
Cui Y; Zhang C; Ma S; Li Z; Wang W; Li Y; Ma Y; Fang J; Wang Y; Cao W; Guan F
J Exp Clin Cancer Res; 2021 Sep; 40(1):294. PubMed ID: 34544449
[TBL] [Abstract][Full Text] [Related]
26. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
[TBL] [Abstract][Full Text] [Related]
27. N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells.
Mo W; Chen Z; Zhang X; Dai G; Ma D; Pan J; Zhang X; Wu G; Fan W
Arterioscler Thromb Vasc Biol; 2022 May; 42(5):644-658. PubMed ID: 35296150
[TBL] [Abstract][Full Text] [Related]
28. PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance.
Zhang Y; Zhou X; Cheng X; Hong X; Jiang X; Jing G; Chen K; Li Y
Neoplasma; 2022 Dec; 69(6):1338-1348. PubMed ID: 36305690
[TBL] [Abstract][Full Text] [Related]
29. N6-methyladenosine demethylase FTO regulates synaptic and cognitive impairment by destabilizing PTEN mRNA in hypoxic-ischemic neonatal rats.
Deng J; Liao Y; Chen J; Chen A; Wu S; Huang Y; Qian H; Gao F; Wu G; Chen Y; Chen X; Zheng X
Cell Death Dis; 2023 Dec; 14(12):820. PubMed ID: 38092760
[TBL] [Abstract][Full Text] [Related]
30. FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.
Sun Z; Sun X; Qin G; Li Y; Zhou G; Jiang X
Epigenetics; 2023 Dec; 18(1):2242688. PubMed ID: 37538000
[TBL] [Abstract][Full Text] [Related]
31. FTO demethylates YAP mRNA promoting oral squamous cell carcinoma tumorigenesis.
Li DQ; Huang CC; Zhang G; Zhou LL
Neoplasma; 2022 Jan; 69(1):71-79. PubMed ID: 34779644
[TBL] [Abstract][Full Text] [Related]
32. Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin.
Wang Y; Cheng Z; Xu J; Lai M; Liu L; Zuo M; Dang L
Bioengineered; 2021 Dec; 12(1):1874-1889. PubMed ID: 34076564
[TBL] [Abstract][Full Text] [Related]
33. The antagonistic effect of FTO on METTL14 promotes AKT3 m
Wei R; Zhao F; Kong L; Pu Y; Li Y; Zang C
J Cancer Res Clin Oncol; 2024 Mar; 150(3):131. PubMed ID: 38491196
[TBL] [Abstract][Full Text] [Related]
34. FTO-Dependent N
Mathiyalagan P; Adamiak M; Mayourian J; Sassi Y; Liang Y; Agarwal N; Jha D; Zhang S; Kohlbrenner E; Chepurko E; Chen J; Trivieri MG; Singh R; Bouchareb R; Fish K; Ishikawa K; Lebeche D; Hajjar RJ; Sahoo S
Circulation; 2019 Jan; 139(4):518-532. PubMed ID: 29997116
[TBL] [Abstract][Full Text] [Related]
35. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
36. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.
Zhang L; Wan Y; Zhang Z; Jiang Y; Lang J; Cheng W; Zhu L
RNA Biol; 2021 Sep; 18(9):1265-1278. PubMed ID: 33103587
[TBL] [Abstract][Full Text] [Related]
37. FTO demethylates m6A modifications in CDKAL1 mRNA and promotes gastric cancer chemoresistance by altering mitochondrial dynamics.
Liu N; Liu C; Wang Z; Wang L; Wang J; Kong J
Clin Exp Pharmacol Physiol; 2023 Apr; 50(4):307-315. PubMed ID: 36628934
[TBL] [Abstract][Full Text] [Related]
38. m
Wang W; He Y; Zhai LL; Chen LJ; Yao LC; Wu L; Tang ZG; Ning JZ
Epigenetics; 2022 Dec; 17(12):1738-1752. PubMed ID: 35404184
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms.
Zhuang X; Liu T; Wei L; Gao J
Front Pharmacol; 2023; 14():1260300. PubMed ID: 37822879
[No Abstract] [Full Text] [Related]
40. m
Wang X; Wu R; Liu Y; Zhao Y; Bi Z; Yao Y; Liu Q; Shi H; Wang F; Wang Y
Autophagy; 2020 Jul; 16(7):1221-1235. PubMed ID: 31451060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
